Amarin Corp Plc (AMRN)

[sts66]

Generics aren't making $300/script - plus their margins are horrible, cost of API is very high. Right now I believe "it's not worth the effort" is a valid POV to have - but with news of Apotex getting approval they must be thinking that AMRN can increase the CVD market and then they can steal it when more API is available. Doesn't cost them anything, they have no sales reps to pay for. As far as DRL's API monopoly lawsuit and FTC complaints, read something today that makes me think there's a non-zero chance that AMRN does get in trouble for locking up all API supply - Broadcom was charged by the FTC for doing something quite similar for the semi-conductors it makes for cable set top boxes and DVRs - case is not identical, but it's damn close:

https://www.ftc.gov/news-events/press-releases/2021/07/ftc-charges-broadcom-illegal-monopolization-orders-semiconductor